Loading organizations...
§ Private Profile · 1000 Massachusetts Ave Ste 101, Cambridge, Massachusetts, 02138, United States
Clinical-stage life sciences company developing drug-free therapies for acute and chronic pain with Neural Ice™ for knee osteoarthritis.
Brixton Biosciences has raised $35.0M across 2 funding rounds.
Key people at Brixton Biosciences.
Brixton Biosciences has raised $35.0M in total across 2 funding rounds.
Brixton Biosciences is a clinical-stage life sciences company developing drug-free therapies for acute and chronic pain management, based in Cambridge, Massachusetts. The organization's lead platform, Neural Ice, delivers long-lasting pain relief through a single injectable nerve block initially targeting knee osteoarthritis before expanding to other indications. To support its commercialization efforts, the biotechnology firm has raised $35.25 million in total funding, including a $35 million Series B round in May 2024. This capital advances its ongoing clinical trials across 11 sites in the United States, targeting potential FDA submission in 2026. Key leadership and backers include Chief Executive Officer Sameer Sabir, investor Joshua Philips, and board member Reggie Groves, a former executive at Medtronic. The enterprise, which currently holds seven filed patents, was spun out of Massachusetts General Brigham and officially founded in 2018.
Brixton Biosciences is a clinical-stage life sciences company developing novel, drug-free injectable therapies for long-lasting pain relief, targeting both acute and chronic pain in the healthcare industry.[1][2][3] Its lead product, ReneuRx™ therapy (powered by the Neural Ice™ platform), delivers ultra-long-acting nerve blocks from a single injection, potentially providing 3 months or more of pain control without addictive systemic drugs, initially focused on knee pain and expanding to multiple indications.[2][3] Originating as a spin-out from Massachusetts General Brigham, the company serves patients, clinicians, and healthcare providers addressing unmet needs in pain management, with strong growth momentum from a $33 million Series B round in May 2024 and plans for further human trials backed by recent $100 million financing.[1][2]
Brixton Biosciences was founded in 2018 in Cambridge, Massachusetts, as a spin-out from Massachusetts General Brigham (including Mass General Hospital), where its ReneuRx™ therapy was developed through years of academic research.[1][2][3] Co-founded by Sameer Sabir, the team includes founders with deep research histories and execution track records from world-class organizations, emphasizing a patient-centric approach led by experienced managers and medical advisors.[2][3][4] Early traction came from preclinical validation of the Neural Ice™ platform, culminating in the first clinical study measuring safety and efficacy for knee pain, followed by the pivotal May 2024 Series B funding to advance human trials.[1][2][3]
Brixton rides the wave of non-opioid pain management innovation, addressing the opioid crisis, rising surgical volumes, aging populations, and escalating healthcare costs driving demand for targeted therapies.[1][2] Timing is ideal amid regulatory support for alternatives to systemic drugs and growing awareness of chronic pain's burden, with market expansion fueled by post-operative needs and patient education.[1] As a biotech spin-out leveraging hospital research, it influences the ecosystem by advancing clinical-stage solutions that could set new standards in regional anesthesia and orthopedics, potentially reducing reliance on short-acting interventions.[2][3]
Brixton is poised to advance Neural Ice™/ReneuRx™ into broader human trials with $100 million+ funding, targeting proof-of-concept across pain indications and regulatory milestones.[1][2] Trends like AI-driven drug discovery, non-addictive therapeutics, and value-based care will accelerate its path, with potential to dominate long-acting injectables if clinical data confirms durability. Its influence may evolve from niche innovator to ecosystem leader, transforming pain control from reactive band-aids to proactive, months-long solutions—echoing its promise of a drug-free revolution.[3][4]
Key people at Brixton Biosciences.
Brixton Biosciences has raised $35.0M across 2 funding rounds. Most recently, it raised $2.0M Grant in October 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 24, 2024 | $2M Grant | — | — | Announced |
| May 14, 2024 | $33M Series B | Schooner Capital | — | Announced |
Brixton Biosciences has raised $35.0M in total across 2 funding rounds.
Brixton Biosciences's investors include Schooner Capital.
